Focal segmental glomerulosclerosis (FSGS) is a kidney disease in which scarring occurs to the glomeruli. Patients with FSGS typically present with nephrotic syndrome, involving edema and proteinuria, but they may also have hypertension, microscopic hematuria, and renal insufficiency at the time of presentation. Owing to FSGS’s various etiologies and differences in presentation, management of the disease must be individualized. RAAS inhibitors are often initiated to reduce proteinuria, and diuretics are commonly used to treat symptoms. Corticosteroid and immunosuppressive therapies are also considered in FSGS associated with clinical features of the nephrotic syndrome. Numerous companies have FSGS therapies in clinical development, and many of these drugs have novel mechanisms of action. If efficacious, these therapies stand to capitalize on the immense need for more effective treatments in this space.
Three KOL interviews in October / November 2020
KEY COMPANIES COVERED
Pfizer, Dimerix Bioscience, Complexa, Travere Therapeutics (formerly Retrophin), Reata Pharmaceuticals, Goldfinch Bio